Miles Capital’s Medicines Co MDCO Stock Holding History

Miles Capital’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,262	Closed	-$208K	–	236
2017 Q1	$208K	Buy	+4,262	New	+$194K	0.12%	184

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Miles Capital's MDCO Position: Q2 2017 in Review

Miles Capital sold out of Medicines Co (MDCO) in Q2 2017, closing a stake of 4,262 shares — an estimated $208K sold.

Miles Capital first reported a position in MDCO in Q1 2017 and held it in 1 quarter. The position peaked at $208K in Q1 2017. 202 funds tracked by Wall St. Rank hold MDCO as of Q2 2017.

Miles Capital reported no remaining Medicines Co position as of Q2 2017 after selling out during the quarter.
Miles Capital sold 4,262 Medicines Co shares in Q2 2017, an estimated $208K.
Miles Capital first reported a position in Medicines Co in Q1 2017 and held it in 1 quarter.
Miles Capital's Medicines Co position peaked at $208K in Q1 2017.
202 funds tracked by Wall St. Rank held Medicines Co as of Q2 2017.

Based on Miles Capital's 13F filing for Q2 2017, filed 14 Aug 2017.